Gilead announces Investigational TLR7 Agonist, HIV Envelope combo data.
Gilead Sciences announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating the combination of a proprietary investigational oral toll-like receptor 7 agonist, GS-9620, and a proprietary investigational broadly neutralizing antibody, PGT121, as part of an HIV eradication strategy. Data from the study conducted in simian-human immunodeficiency virus-infected rhesus monkeys on suppressive antiretroviral therapy demonstrated that a combination treatment of GS-9620 and PGT121 resulted in a subset of animals maintaining viral suppression after ART discontinuation. These data, discussed during a press conference at the 2018 Conference on Retroviruses and Opportunistic Infection in Boston, support further clinical investigation of combination strategies involving bNAbs and a TLR7 agonist which may have the potential to achieve long-term viral suppression without the need for daily ART. After ART discontinuation, 11 of 11 animals in the placebo arm experienced viral rebound with a median rebound time of 21 days, nine of 11 animals that received only PGT121 demonstrated viral rebound and 10 of 11 animals that received only GS-9620 showed viral rebound. In contrast, five of 11 animals that received the combination of PGT121 and GS-9620 demonstrated no viral rebound for at least 168 days, and the other six animals in the combination group rebounded but then began re-suppressing the virus without ART. The proprietary bNAbs PGT121 and GS-9722, as well as the TLR7 agonist GS-9620, are investigational agents and their safety and efficacy have not been established.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 4, 2018|
|Previous Article:||Aimmune presents results from pivotal Phase 3 PALISADE Trial of AR101.|
|Next Article:||Box Office Battle: 'Black Panther' stays at number 1 with $65.7M in third outing.|